Skip to main content
Top

23-04-2024 | Parkinson's Disease | Research Article

Sympathetic dysfunction as an early indicator of autonomic involvement in Parkinson’s disease

Authors: Jin-Woo Park, Luis E. Okamoto, Sung-Hwan Kim, Chan-Nyoung Lee, Kun Woo Park, Seol-Hee Baek, Joo Hye Sung, Namjoon Jeon, Seong-Beom Koh, Alfredo Gamboa, Cyndya A. Shibao, André Diedrich, Byung-Jo Kim, Italo Biaggioni

Published in: Clinical Autonomic Research

Login to get access

Abstract

Purpose

The specific characteristics of autonomic involvement in patients with early Parkinson’s disease (PD) are unclear. This study aimed to evaluate the characteristics of autonomic dysfunction in drug-naïve patients with early-stage PD without orthostatic hypotension (OH) by analyzing Valsalva maneuver (VM) parameters.

Methods

We retrospectively analyzed drug-naïve patients without orthostatic hypotension (n = 61) and controls (n = 20). The patients were subcategorized into early PD (n = 35) and mid-PD (n = 26) groups on the basis of the Hoehn and Yahr staging. VM parameters, including changes in systolic blood pressure at late phase 2 (∆SBPVM2), ∆HRVM3, Valsalva ratio (VR), pressure recovery time, adrenergic baroreflex sensitivity, and vagal baroreflex sensitivity, were assessed.

Results

In the early PD group, ∆SBPVM2, a marker of sympathetic function, was significantly lower compared with that in controls (risk ratio = 0.95, P = 0.027). Receiver operating characteristic (ROC) curve analysis showed an optimal cut-off value of −10 mmHg for ∆SBPVM2 [P = 0.002, area under the curve (AUC): 0.737]. VR exhibited an inverse relationship with Unified Parkinson’s Disease Rating Scale Part 3 scores in the multivariable regression analysis (VR: P = 0.038, β = −28.61), whereas age showed a positive relationship (age: P = 0.027, β = 0.35).

Conclusion

The ∆BPVM2 parameter of the VM may help detect autonomic nervous system involvement in early-PD without OH. Our results suggest that sympathetic dysfunction is an early manifestation of autonomic dysfunction in patients with PD.
Literature
12.
go back to reference Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601. https://doi.org/10.1002/mds.26424CrossRefPubMed Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601. https://​doi.​org/​10.​1002/​mds.​26424CrossRefPubMed
13.
go back to reference Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2015) MDS research criteria for prodromal Parkinson’s disease. Mov Disord 30:1600–1611. https://doi.org/10.1002/mds.26431CrossRefPubMed Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2015) MDS research criteria for prodromal Parkinson’s disease. Mov Disord 30:1600–1611. https://​doi.​org/​10.​1002/​mds.​26431CrossRefPubMed
31.
go back to reference Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A (2021) A phase II study to evaluate the safety and efficacy of prasinezumab in early parkinson’s disease (PASADENA): rationale, design, and baseline data. Front Neurol 12:705407. https://doi.org/10.3389/fneur.2021.705407CrossRefPubMedPubMedCentral Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A (2021) A phase II study to evaluate the safety and efficacy of prasinezumab in early parkinson’s disease (PASADENA): rationale, design, and baseline data. Front Neurol 12:705407. https://​doi.​org/​10.​3389/​fneur.​2021.​705407CrossRefPubMedPubMedCentral
34.
go back to reference Fanciulli A, Jordan J, Biaggioni I, Calandra-Buonaura G, Cheshire WP, Cortelli P, Eschlboeck S, Grassi G, Hilz MJ, Kaufmann H, Lahrmann H, Mancia G, Mayer G, Norcliffe-Kaufmann L, Pavy-Le Traon A, Raj SR, Robertson D, Rocha I, Struhal W, Thijs R, Tsioufis KP, van Dijk JG, Wenning GK (2018) Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS): Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res 28:355–362. https://doi.org/10.1007/s10286-018-0529-8CrossRefPubMedPubMedCentral Fanciulli A, Jordan J, Biaggioni I, Calandra-Buonaura G, Cheshire WP, Cortelli P, Eschlboeck S, Grassi G, Hilz MJ, Kaufmann H, Lahrmann H, Mancia G, Mayer G, Norcliffe-Kaufmann L, Pavy-Le Traon A, Raj SR, Robertson D, Rocha I, Struhal W, Thijs R, Tsioufis KP, van Dijk JG, Wenning GK (2018) Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS): Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res 28:355–362. https://​doi.​org/​10.​1007/​s10286-018-0529-8CrossRefPubMedPubMedCentral
Metadata
Title
Sympathetic dysfunction as an early indicator of autonomic involvement in Parkinson’s disease
Authors
Jin-Woo Park
Luis E. Okamoto
Sung-Hwan Kim
Chan-Nyoung Lee
Kun Woo Park
Seol-Hee Baek
Joo Hye Sung
Namjoon Jeon
Seong-Beom Koh
Alfredo Gamboa
Cyndya A. Shibao
André Diedrich
Byung-Jo Kim
Italo Biaggioni
Publication date
23-04-2024
Publisher
Springer Berlin Heidelberg
Published in
Clinical Autonomic Research
Print ISSN: 0959-9851
Electronic ISSN: 1619-1560
DOI
https://doi.org/10.1007/s10286-024-01031-6